The current stock price of ANGO is 10.05 USD. In the past month the price decreased by -23.63%. In the past year, price decreased by -18.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.29 | 219.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.95 | 207.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.35 | 145.84B | ||
| SYK | STRYKER CORP | 27.88 | 140.43B | ||
| BDX | BECTON DICKINSON AND CO | 14.23 | 58.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.49 | 56.88B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.91 | 49.08B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.21 | 40.16B | ||
| RMD | RESMED INC | 25.35 | 36.63B | ||
| DXCM | DEXCOM INC | 36.79 | 26.69B | ||
| PODD | INSULET CORP | 64.09 | 20.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.63 | 18.64B |
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 675 full-time employees. The company went IPO on 2004-05-27. The firm is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. The company designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
ANGIODYNAMICS INC
14 Plaza Drive
Latham NEW YORK 12110 US
CEO: James C. Clemmer
Employees: 675
Phone: 15187981215
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 675 full-time employees. The company went IPO on 2004-05-27. The firm is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. The company designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
The current stock price of ANGO is 10.05 USD. The price decreased by -7.97% in the last trading session.
ANGO does not pay a dividend.
ANGO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
The Revenue of ANGIODYNAMICS INC (ANGO) is expected to grow by 8.22% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ANGIODYNAMICS INC (ANGO) currently has 675 employees.
The outstanding short interest for ANGIODYNAMICS INC (ANGO) is 5.5% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to ANGO. ANGO may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ANGO reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 72.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.08% | ||
| ROE | -17.95% | ||
| Debt/Equity | 0.03 |
10 analysts have analysed ANGO and the average price target is 18.87 USD. This implies a price increase of 87.76% is expected in the next year compared to the current price of 10.05.
For the next year, analysts expect an EPS growth of -124.4% and a revenue growth 8.22% for ANGO